Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma

Justyna Kmiecik, Andrea Gras Navarro, Aurelie Poli, Jesús Planagumà, Jacques Zimmer, Martha Chekenya*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) with the monoclonal antibody mAb9.2.27 and activated natural killer (NK) cells abrogated the tumor growth and prolonged the survival of glioblastoma-bearing animals by favoring the establishment of a proinflammatory microenvironment. The combination of NK cells and mAb9.2.27 recruited ED1+CCR2low macrophages that stimulated ED1+ED2lowMHCIIhigh microglial cells to exert robust cytotoxicity. Our findings demonstrate the therapeutic potential of targeting salient tumor associated-antigens.

Original languageEnglish
Article numbere27185
JournalOncoImmunology
Volume3
Issue number1
DOIs
Publication statusPublished - 2014

Keywords

  • CNS immunosurveillance
  • CSPG4
  • Glioblastoma
  • NK cells
  • Passive immunotherapy

Fingerprint

Dive into the research topics of 'Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma'. Together they form a unique fingerprint.

Cite this